Literature DB >> 7524760

A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.

L B To1, D N Haylock, T Dowse, P J Simmons, S Trimboli, L K Ashman, C A Juttner.   

Abstract

Peripheral blood (PB) CD34+ cells from four commonly used mobilization protocols were studied to compare their phenotype and proliferative capacity with steady-state PB or bone marrow (BM) CD34+ cells. Mobilized PB CD34+ cells were collected during hematopoietic recovery after myelosuppressive chemotherapy with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) or during G-CSF administration alone. The expression of activation and lineage-associated markers and c-kit gene product were studied by flow cytometry. Proliferative capacity was measured by generation of nascent myeloid progenitor cells (granulocyte-macrophage colony-stimulating factor; CFU-GM) and nucleated cells in a stroma-free liquid culture stimulated by a combination of six hematopoietic growth factors (interleukin-1 (IL-1), IL-3, IL-6, GM-CSF, G-CSF, and stem cell factor). G-CSF-mobilized CD34+ cells have the highest percentage of CD38- cells (P < .0081), but otherwise, CD34+ cells from different mobilization protocols were similar to one another in their phenotype and proliferative capacity. The spectrum of primitive and mature myeloid progenitors in mobilized PB CD34+ cells was similar to their steady-state counterparts, but the percentages of CD34+ cells expressing CD10 or CD19 were lower (P < .0028). Although steady-state PB and chemotherapy-mobilized CD34+ cells generated fewer CFU-GM at day 21 than G-CSF-mobilized and steady-state BM CD34+ cells (P < .0449), the generation of nucleated cells and CFU-GM were otherwise comparable. The presence of increased or comparable numbers of hematopoietic progenitors within PB collections with equivalent proliferative capacity to BM CD34+ cells is not unexpected given the rapid and complete hematopoietic reconstitution observed with mobilized PB. However, all four types of mobilized PB CD34+ cells are different from steady-state BM CD34+ cells in that they express less c-kit (P < .0002) and CD71 (P < .04) and retain less rhodamine 123 (P < .0001). These observations are novel and suggest that different mobilization protocols may act via similar pathways involving the down-regulation of c-kit and may be independent of cell-cycle status.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524760

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Stem cells: From embryology to cellular therapy? An appraisal of the present state of art.

Authors:  Sandro Eridani; Vittorio Sgaramella; Lidia Cova
Journal:  Cytotechnology       Date:  2004-03       Impact factor: 2.058

Review 2.  Autologous peripheral blood stem cells: collection and processing.

Authors:  M Hansson; A Svensson; P Engervall
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

3.  Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization.

Authors:  S J Morrison; D E Wright; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

4.  CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity.

Authors:  Min Cheng; Junlan Zhou; Min Wu; Chan Boriboun; Tina Thorne; Ting Liu; Zhifu Xiang; Qiutang Zeng; Toshikazu Tanaka; Yao Liang Tang; Raj Kishore; Michael H Tomasson; Richard J Miller; Douglas W Losordo; Gangjian Qin
Journal:  Circ Res       Date:  2010-09-16       Impact factor: 17.367

5.  Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells.

Authors:  M L Lozano; F Ortuño; F de Arriba; M C Rosillo; J Rivera; I Heras; V Vicente
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

6.  The human-sheep chimeras as a model for human stem cell mobilization and evaluation of hematopoietic grafts' potential.

Authors:  Graça Almeida-Porada; Christopher Porada; Nicole Gupta; Ali Torabi; David Thain; Esmail D Zanjani
Journal:  Exp Hematol       Date:  2007-10       Impact factor: 3.084

7.  Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).

Authors:  L Tentori; C Leonetti; F Lozupone; E Bonmassar
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

8.  Influence of BMI on level of circulating progenitor cells.

Authors:  Charles F Bellows; Yan Zhang; Paul J Simmons; Amrit S Khalsa; Mikhail G Kolonin
Journal:  Obesity (Silver Spring)       Date:  2011-02-03       Impact factor: 5.002

9.  The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia.

Authors:  Ekati Drakopoulou; Eleni Papanikolaou; Nicholas P Anagnou
Journal:  Stem Cells Int       Date:  2011-11-13       Impact factor: 5.443

10.  Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization.

Authors:  Ingrid G Winkler; Jean Hendy; Paul Coughlin; Anita Horvath; Jean-Pierre Lévesque
Journal:  J Exp Med       Date:  2005-03-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.